TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

Status Completed

Clinical Trial Summary

This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.

Clinical Trial Description

The primary objective of this Phase II clinical trial is to compare the safety and microbiological activity of a moxifloxacin-containing regimen (isoniazid, rifampin, pyrazinamide, moxifloxacin [HRZMoxi]) to a control regimen (isoniazid, rifampin, pyrazinamide, ethambutol [HRZE]) in the first two months of treatment of sputum smear-positive pulmonary tuberculosis. In addition, the study will evaluate whether intermittent administration (thrice-weekly after the first 2 weeks) of these regimens affects their tolerability and microbiological activity. The assessment of microbiological activity will be sputum culture-conversion. Improved sputum culture conversion after 2 months of treatment with a moxifloxacin-containing regimen would support phase 3 clinical trials of moxifloxacin in treatment regimens of less than the current 6 month standard regimens. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00140309
Study type	Interventional
Source	Centers for Disease Control and Prevention
Contact
Status	Completed
Phase	Phase 2
Start date	July 2003
Completion date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06084715` - The INSTITUT Study
Terminated	`NCT03028129` - Prevention of Tuberculosis in Prisons	Phase 4
Not yet recruiting	`NCT06253715` - Shortened Regimen for Drug-susceptible TB in Children	Phase 3
Withdrawn	`NCT03862248` - Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More	Phase 3
Completed	`NCT03271567` - Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
Completed	`NCT03199313` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid	Phase 1
Active, not recruiting	`NCT04919239` - Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)	Phase 2
Active, not recruiting	`NCT03251196` - TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
Recruiting	`NCT05926466` - BTZ-043 Dose Evaluation in Combination and Selection	Phase 2
Recruiting	`NCT04752592` - Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB	N/A
Completed	`NCT04874948` - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment	Phase 1
Not yet recruiting	`NCT04968886` - TuBerculosis Viability Interregional Study and Agreement on Biological Tests
Not yet recruiting	`NCT04485156` - Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)	Phase 3
Active, not recruiting	`NCT02715271` - Study of TB Lesions Obtained in Therapeutical Surgery
Completed	`NCT01364324` - Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Active, not recruiting	`NCT04179500` - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers	Phase 2
Completed	`NCT05899400` - A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
Completed	`NCT04938596` - Airborne Preventive Measures to Reduce New TB Infections in Household Contacts	N/A
Recruiting	`NCT05455112` - Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis	Phase 2
Completed	`NCT03044158` - GeneXpert Performance Evaluation for Linkage to Tuberculosis Care	N/A